Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
Diamyd Medical closes database for phase 3 interim analysis of DIAGNODE‑3
Diamyd Medical has locked the clinical database for the efficacy interim analysis of the phase 3 DIAGNODE‑3 study; results are expected by the end of March 2026. The analysis is based on 174 evaluable participants and measures the change in stimulated C‑peptide AUC to month 15 as a measure of preserved insulin production. An independent Data Safety Monitoring Board is reviewing the interim efficacy and safety data; the company will announce whether the primary endpoint reaches statistical significance. The share price rose sharply on the study progress and market capitalization is about USD 241 million. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | maggio 2026 | |
|---|---|---|
| Ricavi | 6,4K | 7070,57% |
| Utile lordo | -83,07K | 5,13% |
| Utile netto | -11,79 Mln | 192,50% |
| EBITDA | -11,55 Mln | 203,60% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 14,13 Mln € |
Numero di azioni | 151,48 Mln |
Massimo/minimo a 52 settimane | 1,60 € - 0,0803 € |
| Dividendi | No |
Beta | 2,29 |
Rapporto P/E | -0,53 |
Rapporto PEG | 0,03 |
Rapporto P/B | 0,60 |
Rapporto P/S | 366,37 |
Profilo aziendale
Diamyd Medical AB (publ) entwickelt Therapien für die Behandlung von Autoimmundiabetes. Das Unternehmen entwickelt Diamyd, einen antigenspezifischen immuntherapeutischen Diabetes-Impfstoff, der sich in der klinischen Phase IIb für die Behandlung von Typ-1-Diabetes und latentem Autoimmun-Diabetes befindet, sowie Remygen, einen oralen regenerativen und immunmodulatorischen Arzneimittelkandidaten, der sich in der klinischen Phase I/II für die Behandlung von Autoimmun- und Typ-2-Diabetes befindet. Das Unternehmen war früher als Diamyd Therapeutics AB bekannt und änderte im April 2013 seinen Namen in Diamyd Medical AB (publ). Diamyd Medical AB (publ) wurde 1984 gegründet und hat seinen Sitz in Stockholm, Schweden.
| Nome | Diamyd Medical B |
| CEO | Anders Essen-Möller |
| Sede centrale | Stockholm,
ab Svezia |
| Sito web | |
| Quotazione in borsa | 20/05/2013 |
| Dipendenti | 44 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Sto | DMYD-B.ST |
Frankfurt | DMN.F |
Stockholm | DMYD B.ST |
München | DMN.MU |
Scopri gli asset
Gli azionisti di Diamyd Medical B investono anche nei seguenti asset
